select attributes in order to construct the final list of attributes. This study aims to test the feasibility of using the nominal group technique (NGT) to select attributes for DCEs. METHODS: Patients group discussions (4-8 participants) were conducted in Belgium and the Netherlands to prioritize a list of twelve potentially important attributes for osteoporosis drug therapy that were retrieved from literature review and expert discussions. The NGT consisted of three steps: 1) an individual ranking of the twelve attributes by importance from 1 to 12; 2) a group discussion on each of the attributes including a group review of the aggregate score of the initial rankings; and 3) a second ranking task of the same attributes. The selection of attributes for the DCE was based on groups' ranking and NGT discussions followed by experts' discussion. RESULTS: In total, 26 osteoporotic patients participated in five nominal group sessions. Most (80%) patients changed their ranking after the discussion. However, the average initial and final ranking did not markedly differ, with two exceptions. In the final rank, the most important medication attributes were effectiveness, side-effects, frequency and mode of administration. It was also observed that some (15%) patients did not correctly rank from 1 to 12, and the order of attributes did play a role in the ranking. CONCLUSIONS: The nominal group technique is feasible and useful for selecting attributes for DCE, although the ranking task may be cognitively difficult and attributes order should vary over different NGT sessions.
HAQ-DI [Difference -0.52 (95% CrI -0.73, -0.31)] compared with placebo, and was at least as efficacious compared to aTNF monotherapy [Difference -0.16 (95% CrI -0.33, 0.01)]. Insufficient data was reported for the SF-36 and fatigue to allow network meta-analysis. CONCLUSIONS: Based on network meta-analysis of currently available RCT evidence, involving indirect comparison of trial findings, tocilizumab monotherapy was found to have better outcomes than assessed aTNF monotherapies in terms of patient reported pain and disease activity in a DMARD-IR RA population. Tocilizumab was at least as efficacious as aTNF agents in improvement in physical function.
PMS65 DETECTING POTENTIAL FIBROMYALGIA PATIENTS IN PRIMARY CARE SETTINGS: VALIDATION OF THE FIBRODETECT SCREENING TOOL
Gilet H 1 , Dias-barbosa C 1 , Guillemin I 1 , Baron R 2 , Perrot S 3 , Alegre C 4 , Choy E 5 , Cruccu G 6 , Desmeules J 7 , Margaux J 8 , Richards S 9 , Serra E 10 , Spaeth M 11 , Arnould B 1 1 MAPI Consultancy, Lyon, France, Kiel, Germany, 3 Hospital Hotel Dieu, Paris, France, 4 Hospital Universitari Valle d'Hebron, Barcelona, Spain, 5 Cardiff University, Cardiff, UK, 6 La Sapienza University, Roma, Italy, 7 Geneva University Hospital, Geneva, Switzerland, 8 Erasme Hospital, Brussels, Belgium, 9 Poole Hospital NHS Trust, Poole, UK, 10 Amiens University Hospital, Amiens, France, 11 Center for Clinical Rheumatology, Gräfelfing, Germany OBJECTIVES: To validate and determine the discriminative power of the FibroDetect ® screening tool in helping primary care physicians detect patients with fibromyalgia in routine practice. METHODS: The FibroDetect included 14 questions assessing patients' pain and fatigue, personal history and attitudes, symptoms and impact on lives. To discriminate between American College of Rheumatology positive (ACRϩ) patients and ACR negative (ACR-) patients (nϭ276), a scoring method was created using an iterative process based on statistical and clinical considerations. The discriminant model was then validated with fibromyalgia and nonfibromyalgia patients (nϭ312). A score threshold for individual ACR classification was defined. RESULTS: Of the 14 original FibroDetect questions, six questions were retained in the final scoring, demonstrating discriminative power between ACRϩ and ACR-patients with an area under the ROC curve of 0.74. A majority of ACRϩ patients (77%) and less than half of ACR-(39%) had a score Ն 6, suggesting that patients with such score are likely to be ACRϩ, and should thus be referred to a fibromyalgia specialist. A total of 8% of ACRϩ patients and 79% of ACR-patients had a score Յ 3, suggesting that patients with such score were unlikely to be ACRϩ, and should thus be not be referred to a fibromyalgia specialist. Patients with a FibroDetect score of 4 or 5 would require further investigation. The predictive accuracy of the tool increased to 0.86 for fibromyalgia and non-fibromyalgia patient detection. With a 6-point cut-off, the sensitivity was 90% and the specificity was 67% for fibromyalgia and non-fibromyalgia patient detection. CONCLUSIONS: The FibroDetect is a screening tool that detects potential fibromyalgia patients among patients with chronic widespread pain. It can be used as a surrogate for ACR classification criteria in primary care settings, and improve referral to appropriate specialist.
PMS66 THE MYOTONIC DYSTROPHY TYPE-1 HEALTH INDEX (MDHI): AN ANALYSIS OF ITS ABILITY TO DIFFERENTIATE BETWEEN CLINICALLY DISTINCT POPULATIONS
Heatwole C 1 , Bode R 2 , Dekdebrun J 1 , Dilek N 1 , Johnson N 1 , Luebbe E 1 , Martens W 1 , Thornton C 1 , Moxley RT 1 1 The University of Rochester, Rochester, NY, USA, 2 Rehabilitation Institute of Chicago, Chicago, IL, USA OBJECTIVES: Myotonic dystrophy type-1 (DM1) is a dominantly inherited disorder caused by an unstable CTG repeat expansion on chromosome 19. Clinically the disease is associated with a wide variety of symptoms. The Myotonic Dystrophy Health Index (MDHI) is a disease-specific patient reported outcome measure designed to measure total health, and 17 of the most important areas of diseasespecific health in DM1. The items in this instrument were selected utilizing qualitative interviews and a cross-sectional study of 278 patients. The MDHI's total score (and each of the 17 subscales) are scored from 0-100 with 100 representing the highest level of disease. The objective of this research is to evaluate the MDHI's ability to differentiate between known groups of DM1 patients. METHODS: Each of the MDHI's 17 subscales was completed by a group of DM1 patients. DM1 respondents were divided into known groups by employment status, CTG repeat number (Ͻ300,300ϩ), education (non-college graduate, college graduate), age (21-46,47ϩ years), and duration of symptoms (Ͻ21,21ϩ years). The average subscale score and total MDHI score was calculated for each known group. RESULTS: On average, 138 DM1 patients completed each subscale. The MDHI measured a higher disease burden in patients who were unemployed (MDHI total score: 41.5 vs. 25.0), less educated (41.4 vs. 33.8), had a longer duration of symptoms (41.3 vs. 34.6), were of older age (38.3 vs. 33.1) and those with a longer CTG repeat number (35.6 vs. 27.6) . CONCLUSIONS: The MDHI and its subscales are capable of differentiating between known groups of DM1 patients who are suspected of having a higher burden of disease.
PMS67

LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL COMBINATION AND MONOTHERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
OBJECTIVES:
The current analysis evaluates the long-term impacts on household productivity and social participation of CZP 400mg Q4W combination and monotherapy over 5 years. METHODS: In this open-label extension (OLE) (NCT00160693) patients (pts) originally enrolled in FAST4WARD (NCT00548834) or study 014 (NCT00544154) received CZP 400 mg Q4W for 24 wks. Pts who completed or withdrew on/after Wk12 in either study were eligible and were permitted to take DMARDs in OLE. Household productivity and social participation were assessed through the RA-specific Work Productivity Survey (WPS-RA); results are reported up to Wk268 (5.2yrs). The analyzed population consisted of (1) Wk 24 CZP completers from FAST4WARD (Nϭ75) or 014 (Nϭ96) who entered the OLE (all pts group) and (2) FAST4WARD CZP completers who entered OLE and did not receive MTX/ DMARDs (Nϭ48) (monotherapy subgroup). RESULTS: In both populations analyzed, a rapid reduction in the number of days of household work days missed per month was seen from feeder study baseline (BL, 7.4 and 11.1 mean days respectively) over 24wks of the feeder studies to OLE entry (3.5 and 4.1 mean days respectively) and continued to decline over time, up to Week 268 (1.2 and 1.4 mean days respectively). Increased participation in family/social/leisure activities was reported in both populations, with a decrease in the number of days missed per month from feeder study baseline (4.4 and 6.2 mean days, respectively), to entry to OLE, at a mean of 1.3 and 1.1 days respectively for monotherapy pts; improvements continued over the 5 years to 0.4 and 0.2 days on average in the 2 populations respectively. CONCLUSIONS: CZP treatment, in combination with MTX/DMARDs or as monotherapy, rapidly decreased the number of household work or social/family/leisure days missed per month. These improvements were maintained up to 5 years with open-label CZP following 24 wks double-blind CZP therapy.
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PMS68 THE USE OF MONITORING SYSTEMS TO BETTER REGULATE DRUG CONSUMPTION IN HUNGARIAN HOSPITALS
Ecseki A, Becsi R, Toth I, Rozsa P, Gerencser Z MediConcept Ltd., Budapest, Hungary OBJECTIVES: Due to the global economic crisis, most of the actions of the Hungarian government are focused on cost reductions, including in the health care sector. According to the ownership structure's changes (i.e., the state becoming the owner), the most important thing is to create a well-monitored and centralized hospital system. In addition to these changes, the government seeks to centralize the procurement of pharmaceuticals and medical equipment at state-owned hospitals. METHODS: We have prepared literature review and interviews with high level hospital and political leaders to find how can we strengthen the regulation of drug consumption at hospitals, which is at this time without strict controls. RESULTS: Due to the specific objectives of the HunDRG system, which are focused more on monitoring the number of DRG cases than tracking resources, there are no incentives for hospitals to maintain strict inventories of their drugs. Except for biological drugs, which use an itemized financing system, there is no pressure by the government to monitor the medical costs at the unit level; as such, only hospital data exists. Based on IMS data in 2011, the total hospital sector was valued at approximately 100 billion HUF. Most of the hospitals do not have adequate computer systems to monitor the patient-level data. CONCLUSIONS: In conclusion, the so called unit-dose system could be a good solution to measure the drug consumption at the patient level and to improve drug security (trial system). To sum up, it is very important to gain more data regarding the Hungarian hospital system to be able to create a sustainable, transparent, highly-regulated, and centralized public health care system.
PMS69 KEY DRIVERS FOR PRICING AND REIMBURSEMENT FOR BIOLOGIC DRUGS IN FRANCE
Niklitschek T 1 , Williams AE 2 , Storer M 3 1 University of Cambridge, Cambridge, UK, 2 MedImmune Limited, Cambridge, UK, 3 PriceSpective, London, UK OBJECTIVES: In France, the reimbursement decisions and price negotiations for new drugs are highly influenced by the National Authority of Health (HAS) recommendations communicated in the formal health technology assessment (HTA). This study aimed to analyse past criterions and consider future possible requirements influencing future submissions. METHODS: A convenient internet literature review was conducted to identify categories for value drivers in the evaluation of the incremental medical benefit (ASMR) for a new product. An analysis of five biological products reviewed 2006-2012 for rheumatology disorders was conducted using these criterions. Based on the findings, exploratory interviews with two ex-HAS members were performed to gain insight into future potential evidence requirements. RESULTS: From the literature review three categories of evidence were developed. Firstly 'socioeconomics', to include the French payers' perspective of burden and cost of illness. The second category was 'clinical evidence', evaluating the added therapeutic value for a target population, the clinical efficacy and safety. The third category was 'real world data', to establish effectiveness and long-term safety post-launch. From the analysis it was demonstrated that only products targeting patients with an insufficient response to anti-TNFs were recommended a high -level II-ASMR. Only 2 of 14 phase III studies used an active comparator in Phase III superiority studies. Open label extension studies were commonly used to provide post-launch data. Findings of the interviews suggested that in the future superiority verses current standard of care in France for a clear target population would be the expectation for an ASMR Յ IV from the HAS. CONCLUSIONS: These findings emphasise the need to integrate payer evidence requirements into the clinical development strategy early on. Effort should be directed towards the identification of a clear target population demonstrating superior efficacy to standard of care.
